Biodesix year-end earnings beat analyst expectations as COVID testing revenue rises
BOULDER — Lung cancer testing company Biodesix Inc. (Nasdaq: BDSX) beat Wall Street estimates in its latest round of earnings, including more than doubling its expected revenue.
The Boulder company posted revenues of $27.03 million for the final three months of 2020, beating consensus estimates by $11.56 million, according to data compiled by finance site Seeking Alpha. Its loss of 25 cents per share beat estimates by 9 cents.
COVID-19 testing was the main driver of revenues for the quarter, bringing in $21.4 million for the company. Biodesix and its partner Bio-Rad Laboratories Inc. (NYSE: BIO) worked to develop active-infection and antigen…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Playa Bowls, a national restaurant chain specializing in fruit bowls and smoothies, will soon open…
-
Underground Printing LLC, a Michigan-based producer of custom printed apparel, promotional products and licensed collegiate…
-
The City of Boulder has launched an Affordable Commercial Grant Pilot Program to help businesses…
-
After losing its Colorado center in the Marshall Fire, spiritual group Diamond Approach will celebrate…
